Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants

Pediatrics

Volumn 121, Issue 1, 2008, Pages 22-27

  Malcolm, William F ^a,d   Gantz, Marie ^b   Martin, Richard J ^c   Goldstein, Ricki F ^a   Goldberg, Ronald N ^a   Cotten, Charles M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RTI INTERNATIONAL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antacid; Development; Gastroesophageal reflux; Growth; Infant; Low birth weight; Premature

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; RANITIDINE;

ARTICLE; CHILD GROWTH; COGNITIVE DEFECT; COHORT ANALYSIS; DRUG EFFECT; DRUG INDICATION; DRUG USE; EXTREMELY LOW BIRTH WEIGHT; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GESTATIONAL AGE; GROWTH DISORDER; HOSPITAL DISCHARGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

BODY WEIGHT; CHILD DEVELOPMENT; COHORT STUDIES; CONTINUITY OF PATIENT CARE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FAMOTIDINE; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; METOCLOPRAMIDE; PATIENT DISCHARGE; RANITIDINE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 38049021479     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2007-0381     Document Type: Article

References (22)

1. Peter CS, Sprodowski N, Bohnhorst B, Silny J, Poets CF. Gastroesophageal reflux and apnea of prematurity: no temporal relationship. Pediatrics. 2002;109:8-11
2. Barrington KJ, Tan K, Rich W. Apnea at discharge and gastroesophageal reflux in the preterm infant. J Perinatol. 2002;22:8-11
3. Molloy EJ, Di Fiore JM, Martin RJ. Does gastroesophageal reflux cause apnea in preterm infants? Biol Neonate. 2005;87:254-261
4. Kimball AL, Carlton DP. Gastroesophageal reflux medications in the treatment of apnea in premature infants. J Pediatr. 2001;138:355-360
5. Snel A, Barnett CP, Cresp TL, et al. Behavior and gastroesophageal reflux in the premature neonate. J Pediatr Gastroenterol Nutr. 2000;30:18-21
6. Frakaloss G, Burke G, Sanders MR. Impact of gastroesophageal reflux on growth and hospital stay in premature infants. J Pediatr Gastroenterol Nutr. 1998;26:146-150
7. Ferlauto JJ, Walker MW, Martin MS. Clinically significant gastroesophageal reflux in the at-risk premature neonate: relation to cognitive scores, days in the NICU, and total hospital charges. J Perinatol. 1998;18:455-459
8. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117:1979-1987
9. Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2006;117(2). Available at: www.pediatrics.org/cgi/ content/full/117/2/e137
10. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;(314):1-27
11. Bayley N. Manual for the Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corp; 1993
12. Cotten CM, Oh W, McDonald S, et al. Prolonged hospital stay for extremely premature infants: risk factors, center differences, and the impact of mortality on selecting a best-performing center. J Perinatol. 2005;25:650-655
13. Tyson JE, Younes N, Verter J, Wright LL. Viability, morbidity, and resource use among newborns of 501- to 800-g birth weight. JAMA. 1996;276:1645-1651
14. Rudolph CD, Mazur LJ, Liptak GS, et al. Pediatric gastroesophageal reflux clinical practice guidelines. J Pediatr Gastroenterol Nutr. 2001;32(suppl 2):1-31
15. Mehall JR, Kite CA, Saltzman DA, Wallett T, Jackson RJ, Smith SD. Prospective study of the incidence and complications of bacterial contamination of enteral feeding in neonates. J Pediatr Surg. 2002;37:1177-1182
16. Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics. 2006;118:746-752
17. Dhillon AS, Ewer AK. Diagnosis and management of gastrooesophageal reflux in preterm infants in neonatal intensive care units. Acta Paediatr. 2004;93:88-93
18. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007;196:147.e1-147.e8
19. Wenzl TG, Moroder C, Trachterna M, et al. Esophageal pH monitoring and impedance measurement: a comparison of two diagnostic tests for gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 2002;34:519-523
20. Latal-Hajnal B, von Siebenthal K, Kovari H, Bucher HU, Largo RH. Postnatal growth in VLBW infants: significant association with neurodevelopmental outcome. J Pediatr. 2003;143:163-170
21. Reilly S, Skuse D, Poblete X. Prevalence of feeding problems and oral motor dysfunction in children with cerebral palsy: a community survey. J Pediatr. 1996;129:877-882
22. Mizuno K, Ueda A. Neonatal feeding performance as a predictor of neurodevelopmental outcome at 18 months. Dev Med Child Neurol. 2005;47:299-304